NASDAQ:ECOR - Electrocore Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.87 -0.39 (-5.37 %) (As of 02/15/2019 04:00 PM ET)Previous Close$6.87Today's Range$6.80 - $7.3952-Week Range$4.16 - $20.25Volume75,412 shsAverage Volume134,279 shsMarket Capitalization$195.30 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey. Receive ECOR News and Ratings via Email Sign-up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ECOR Previous Symbol CUSIPN/A Webwww.electrocore.com Phone973-290-0097Debt Debt-to-Equity RatioN/A Current Ratio17.85 Quick Ratio17.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$810,000.00 Price / Sales241.11 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees64 Outstanding Shares28,428,000Market Cap$195.30 million OptionableNot Optionable Electrocore (NASDAQ:ECOR) Frequently Asked Questions What is Electrocore's stock symbol? Electrocore trades on the NASDAQ under the ticker symbol "ECOR." How were Electrocore's earnings last quarter? Electrocore (NASDAQ:ECOR) posted its earnings results on Tuesday, November, 13th. The company reported ($0.45) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.45). The firm had revenue of $0.15 million for the quarter. View Electrocore's Earnings History. When is Electrocore's next earnings date? Electrocore is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Electrocore. What price target have analysts set for ECOR? 3 analysts have issued 12 month target prices for Electrocore's shares. Their forecasts range from $20.00 to $23.00. On average, they anticipate Electrocore's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 213.0% from the stock's current price. View Analyst Price Targets for Electrocore. What is the consensus analysts' recommendation for Electrocore? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Electrocore in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Electrocore. What are Wall Street analysts saying about Electrocore stock? Here are some recent quotes from research analysts about Electrocore stock: 1. According to Zacks Investment Research, "Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. " (1/10/2019) 2. BTIG Research analysts commented, "Q3 report surprised us with revenue well below estimates (~$150K vs our ~$1M) but strong patient and physician demand. With over 4500 prescriptions in the quarter – and about 2000 scripts in October alone – there is clearly prescriber/patient enthusiasm for gammaCore. But early reimbursement wins are taking longer than expected to turn into sales. At this time almost all patients are receiving the device through sample and copay assistance programs, with important payor coverage catalysts slated for early 2019. With patients getting gammaCore for free at this point and then pushing insurers to eventually cover it, it is difficult to determine how prescribing trends may evolve as reimbursement becomes the norm and as ECOR eventually must require payment." (11/15/2018) Has Electrocore been receiving favorable news coverage? News articles about ECOR stock have trended neutral on Saturday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Electrocore earned a news impact score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. Are investors shorting Electrocore? Electrocore saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,094,230 shares, an increase of 43.1% from the December 31st total of 764,591 shares. Based on an average daily volume of 266,839 shares, the days-to-cover ratio is currently 4.1 days. Currently, 6.2% of the shares of the stock are sold short. View Electrocore's Current Options Chain. Who are some of Electrocore's key competitors? Some companies that are related to Electrocore include Viewray (VRAY), AxoGen (AXGN), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Cutera (CUTR), Helius Medical Technologies (HSDT), Zynex (ZYXI), Fonar (FONR), Stereotaxis (STXS), Edap Tms (EDAP), BioSig Technologies (BSGM), IRIDEX (IRIX), Second Sight Medical Products (EYES) and Soleno Therapeutics (SLNO). Who are Electrocore's key executives? Electrocore's management team includes the folowing people: Mr. Francis R. Amato, CEO & Director (Age 54)Mr. Joseph P. Errico, Co-Founder, Chief Science & Strategy Officer, Principal Investor & Director (Age 49)Mr. Glenn S. Vraniak, Chief Financial Officer (Age 55)Dr. Peter S. Staats, Chief Medical Officer (Age 55)Mr. Steven M. Mendez, Founder & CTO (Age 57) When did Electrocore IPO? (ECOR) raised $64 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities served as the underwriters for the IPO and BTIG was co-manager. When did the company's lock-up period expire? Electrocore's lock-up period expired on Wednesday, December 19th. Electrocore had issued 5,200,000 shares in its initial public offering on June 22nd. The total size of the offering was $78,000,000 based on an initial share price of $15.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Electrocore's major shareholders? Electrocore's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Hodges Capital Management Inc. (2.43%), RTW Investments LP (1.82%), BlackRock Inc. (0.99%), Lord Abbett & CO. LLC (0.76%), Northern Trust Corp (0.23%) and Geode Capital Management LLC (0.16%). Company insiders that own Electrocore stock include Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, Joseph P Errico and Peter S Staats. View Institutional Ownership Trends for Electrocore. Which major investors are selling Electrocore stock? ECOR stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC and Hodges Capital Management Inc.. View Insider Buying and Selling for Electrocore. Which major investors are buying Electrocore stock? ECOR stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Two Sigma Investments LP, Geode Capital Management LLC, Wsfs Capital Management LLC, Suffolk Capital Management LLC, New York State Common Retirement Fund, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought Electrocore stock in the last two years include Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck and Peter S Staats. View Insider Buying and Selling for Electrocore. How do I buy shares of Electrocore? Shares of ECOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Electrocore's stock price today? One share of ECOR stock can currently be purchased for approximately $6.87. How big of a company is Electrocore? Electrocore has a market capitalization of $195.30 million and generates $810,000.00 in revenue each year. Electrocore employs 64 workers across the globe. What is Electrocore's official website? The official website for Electrocore is http://www.electrocore.com. How can I contact Electrocore? Electrocore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company can be reached via phone at 973-290-0097 or via email at [email protected] MarketBeat Community Rating for Electrocore (NASDAQ ECOR)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 60 (Vote Outperform)Underperform Votes: 68 (Vote Underperform)Total Votes: 128MarketBeat's community ratings are surveys of what our community members think about Electrocore and other stocks. Vote "Outperform" if you believe ECOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECOR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?